SUMMIT (COPD)
Study to Understand Mortality and Morbidity in COPD
Paciente / Población Intervención / Exposición Comparación Desenlace
In 16,485 patients with moderate COPD and CVD or high CV risk, fluticasone furoate-vilanterol did not reduce all-cause mortality compared with placebo.
N
16.485
Diseño
Multicentre RCT, 4-arm
Desenlace
All-cause mortality
Relevancia
3
ResultadoHR 0.88 (95% CI 0.74–1.04; p=0.137). No effect on the composite CV outcome.
Vestbo J, et al. Lancet. 2016;387(10030):1817-1826. 10.1016/S0140-6736(16)30069-1
Discusión y crítica
Definitive negative trial of ICS/LABA mortality benefit in CV-enriched COPD; directly relevant to cardiology consultation.